logo
Should you buy OPD insurance? Get the complete lowdown to help you decide.

Should you buy OPD insurance? Get the complete lowdown to help you decide.

Mint3 days ago

Imagine this: you have some health issues and visit a doctor. She prescribes you medicines and a couple of diagnostic tests. You pay a good amount of money for the doctor's consultation, medicines and tests, and wonder whether your health insurance policy will cover it.
Well, here's the bad news: most health insurance policies do not cover outpatient department (OPD) expenses. According to a report by India Insurtech Association, India's OPD spending amounted to a massive $37.7 billion in FY24, of which retail OPD insurance accounted for less than 0.1%.
Noting this gap, insurers have of late started to offer OPD coverage and healthcare startups have also entered the space, providing OPD subscription plans directly to customers or via employers.
Here's a lowdown of what all is available.
OPD plans from insurers
India's OPD market is highly fragmented, so providing coverage is difficult. The high chances of billing fraud can't be ignored, so insurers prefer to offer OPD coverage on a cashless basis, allowing you to only visit their network partners for doctor consultations and diagnostics.
Some insurers may agree to reimburse the cost incurred at non-network facilities as well. Among popular plans, as shared by Policybazaar.com, ICICI Lombard's Elevate comes with an OPD+ rider. The premium varies by age. A 35-year-old male must pay ₹4,980 annually for ₹10,000 OPD coverage in a year. The plan only works on a cashless model and has no sub-limits on procedures such as dental and vision.
Bajaj Allianz's Health Prime and Niva Bupa's Acute-Best Care offer both cashless facilities and reimbursements. The former has a premium of 2,062 for ₹15,000 coverage while latter costs ₹4,801 for ₹10,000 coverage for a 35-year old individual.
Niva Bupa's Well Consult-OPD puts a co-payment of 20% if a policyholder files for reimbursement. Star Health Insurance has a standalone OPD insurance policy that allows cashless and reimbursement only for accident-related emergencies. A 35-year old individual will pay ₹4,802 for ₹25,000 coverage. This plan has a waiting period of 1-3 years for OPD expenses of pre-existing diseases.
"Traditionally the OPD plans had sub-limits on doctor consultation, diagnostic tests or pharmacy bills. For example, the OPD sum insured could very well be ₹20,000 but pharmacy bills having a sub-limit of ₹5,000. But insurers are increasingly launching plans with no sub-limits for customers to utilise the OPD benefit in the way they want," said Siddharth Singhal, business head - health insurance, Policybazaar.com.
Direct-to-consumer plans
Lucknow-based Geeta Srivastava (66) heard about healthcare startup LivLong's OPD plan Eldercare. "The plan costs me ₹12,000 a year. OPD benefits such as medicines and lab tests are restricted to ₹3,000 a year, but there are other useful benefits such as full-body check-up (83 parameters), unlimited consultation with doctors and nutritionists, six consultations a year with specialists and two free ambulance services. Another benefit is having a healthcare manager at my disposal who checks up on me every now and then and helps me with what I require," Srivastava said.
Data from LivLong showed they have three plans, priced at ₹5500, ₹6,000 and ₹11,599. "These plans have a perceived value of ₹15,000, ₹16,000 and ₹28,800, respectively," said Gaurav Dubey, founder & CEO, LivLong 365.
To be sure, there is no underlying sum insured in LivLong OPD plans. They offer up to 50% discounts on OPD benefits such as consultations, lab tests, diagnostics and medicines, which translate into perceived savings.
Healthcare provider Even Health offers OPD insurance in partnership with Magma General Insurance. However, you can't buy standalone OPD cover from them. You need to buy IPD cover (sum insured ranges from ₹3 lakh to ₹1 crore) in which OPD cover of ₹10 lakh will be inlcuded if you pay extra over the premium. People aged 0-35 years can buy it for around 4,500 a year, 36-49 years for ₹10,000 a year, and over 50 for ₹19,000 a year, excluding the premium for IPD coverage.
"Our OPD plan works everywhere in the country on a cashless basis. We have partners in every pin code from Lakshadweep to Leh. We not only cover doctor's consultations but also diagnostic (radiology, pathology) and medicines. We offer reimbursement, too, but with 50% co-pay," said Mayank Banerjee, Co founder, Even.in.
Coverage from your employer
Companies such as Onsurity and Plum, or for that matter even Even Health and LivLong, curate OPD coverage in partnership with employers to offer it to employees.
Noida-based Anmol Bhushan (28) works with a financial services firm as an actuarial consultant. His employer offers OPD benefits as part of its wellness services. He pays ₹11,000 per year to insure himself and his parents for a maximum benefit of ₹21,000. "The plan has a co-payment of 10% for me and 20% for my parents. Each year I manage to avail of at least ₹18,000 benefit," said Bhushan.
Data from Onsurity shows their wellness OPD plans cost a minimum of ₹145 more per member per month and can go up to ₹4,500 or more based on the features. "Pricing retail OPD plans at a low cost is difficult because the utilisation will be high in those plans. We offer it to them via employers so that the utilisation is comparatively lower and we can keep the pricing viable," said Suman Pal, chief claims officer at Onsurity.
Can't argue with free
Some employers offer the benefit to employees for free. Mumbai-based Dipen Chheda (50) for example, used it while he was working with his previous employer. "The challenge in that plan was the limited number of associated partners. If I have to take doctor consultation and no network doctor is available nearby, it does not make sense for me to go far. Similarly, nearby chemists also offer discounts on medicines. Sometimes those are better than what OPD cover offers," he said.
For Bengaluru-based Shobhit Katikia (27), the experience has been great. "We get a flat coverage of ₹20,000 per year from our employer. I don't have to pay for it. It covers me and my parents. I availed the claim twice in the past two years – for dental treatment that included the procedure and medicines in the first year, and for new glasses in the second year. The cost of the eye check-up, frame and lens was all covered," he said. In his case, he could choose any doctor or pharmacy and file for reimbursement. "The claims were approved in 24 hours," he said.
Should you buy an OPD plan?
Well, it depends on the cashless network the platform provides, and the sub-limits. "We have noticed that doctors empaneled with different such platforms may just have an MBBS degree and not really be specialists. The way the OPD market works is people may want to visit specialists and diagnostic centres of their choice. We are in the process of launching retail OPD cover, which will address these issues," said Saurabh Vijayvergia. founder & CEO, CoverSure.
Mint's take
India's OPD insurance market is at a nascent stage. While employer-linked OPD cover offers decent benefits, there are very few direct-to-customer options from healthcare startups. There is greater variety in policies offered by insurers. Whichever option you choose, sub-limits on various benefits make such plans restrictive. You could considering buying it to giving it a try if you can afford it.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Torrent Pharma to acquire majority stake in KKR-backed JB Chemicals at  ₹25,689 crore valuation — Details here
Torrent Pharma to acquire majority stake in KKR-backed JB Chemicals at  ₹25,689 crore valuation — Details here

Mint

time34 minutes ago

  • Mint

Torrent Pharma to acquire majority stake in KKR-backed JB Chemicals at ₹25,689 crore valuation — Details here

Gujarat-based pharmaceutical giant Torrent Pharma announced on Sunday, 29 June 2025, that it is in definitive agreements with global investment giant KKR to acquire a majority stake in JB Chemicals, according to an exchange filing. The potential acquisition details show that the company plans to acquire J. B. Chemicals and Pharmaceuticals (JB Pharma) at an equity valuation of ₹ 25,689 crore on a fully diluted basis, which will be followed by a merger of the two companies. JB Pharma's promoter company, Tau Investment Holdings, is a KKR-owned investment vehicle which the global giant uses to own a stake in the pharma major. Tau Investment is a legally distinct legal entity of KKR & Co. Inc. Tau Investment currently holds a 47.84% stake in J. B. Chemicals and Pharmaceuticals, according to BSE data as on Sunday, 29 June 2025. The deal is set to be carried out in several phases. In the first phase, Torrent Pharma will acquire a 46.39% stake through a share purchase agreement (SPA), which will total ₹ 11,917 crore at the rate of ₹ 1,600 per share. After the first phase, the company will introduce a mandatory open offer to acquire up to 26% of JB Pharma shares from public stakeholders at an open offer price of ₹ 1,639.18 per share. The acquiring company also plans to acquire another 2.80% stake in the company from certain employees holding a stake of JB Pharma at the same price per share as KKR selling its stake. The company also announced its plans for a merger between Torrent and JB Pharma through a scheme of arrangement where every shareholder holding 100 shares in JB Pharma will receive 51 shares of Torrent Pharmaceuticals. 'We are pleased to have on board the JB Pharma heritage and build on the platform for the future. Torrent's deep India presence and JB Pharma's fast-growing India business, combined with the CDMO and international footprint offers immense potential to scale both revenue and profitability,' said Samir Mehta, the Executive Chairman of Torrent Pharma in the official statement. JB Chemicals & Pharmaceuticals shares closed 2.72% higher at ₹ 1,799.35 after Friday's stock market session, compared to ₹ 1,751.75 in the previous market close. Shares of the pharma company have given more than 398% returns on investment in the last five years. However, the stock has lost 0.03% in the last one-year period. On a year-to-date (YTD) basis, the shares are down 4.58% in 2025, but are currently trading 6.02% higher in the last one-month period. Torrent Pharmaceuticals shares also closed with 3.68% gains on Friday's market at ₹ 3,344.40, compared to ₹ 3,225.70 in the previous stock market session last week. Pharma major Torrent Pharmaceuticals shares have gained 181% in the last five years and are trading 21.35% higher in the last one-year period. The shares are trading 6.94% higher in the last five trading sessions. Read all stories by Anubhav Mukherjee Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.

Buyer found for TikTok, identities to be revealed soon, says Donald Trump
Buyer found for TikTok, identities to be revealed soon, says Donald Trump

Business Standard

time42 minutes ago

  • Business Standard

Buyer found for TikTok, identities to be revealed soon, says Donald Trump

US President Donald Trump said in a Fox News interview broadcast on Sunday that he had found a buyer for the TikTok short-video app, which he described as a group of "very wealthy people" whose identities he will reveal in about two weeks. Trump made the remarks in an interview on Fox News ' "Sunday Morning Futures with Maria Bartiromo" program. He said the deal he is developing would probably need China's approval to move forward and he predicted Chinese President Xi Jinping would likely approve it. The US president earlier this month had extended to September 17 a deadline for China-based ByteDance to divest the U.S. assets of TikTok despite a law that mandated a sale or shutdown without significant progress. A deal had been in the works this spring that would have spun off TikTok's U.S. operations into a new U.S.-based firm, majority-owned and operated by U.S. investors, but it was put on hold after China indicated it would not approve it following Trump's announcements of steep tariffs on Chinese goods. "We have a buyer for TikTok, by the way," Trump said. "I think I'll need probably China's approval. I think President Xi will probably do it." A 2024 U.S. law required TikTok to stop operating by January 19 unless ByteDance had completed divesting the app's U.S. assets or demonstrated significant progress toward a sale. Trump, who credits the app with boosting his support among young voters in last November's presidential election, has extended the deadline three times.

Cloud kitchens operator Curefoods files IPO papers; aims to raise Rs 800-cr
Cloud kitchens operator Curefoods files IPO papers; aims to raise Rs 800-cr

Business Standard

time42 minutes ago

  • Business Standard

Cloud kitchens operator Curefoods files IPO papers; aims to raise Rs 800-cr

Cloud kitchens operator Curefoods India on Sunday filed preliminary papers with markets regulator Sebi seeking its approval to raise funds through an initial public offering (IPO). The proposed IPO is a combination of fresh issuance of shares worth Rs 800 crore, and an offer-for-sale of 4.85 crore equity shares by existing shareholders, according to the draft red herring prospectus (DRHP). As part of the OFS, Curefit Healthcare, Iron Pillar PCC, Crimson Winter, Accel India V, Chiratae Ventures India Fund IV, Global eCommerce Consolidation Fund and Alteria Capital Fund will be offloading shares. The Bengaluru-based Curefoods India, which operates CakeZone and Nomad Pizza, plans to mobilise up to Rs 160 crore in pre-IPO round. If it completes the pre-IPO placement, then the size of the fresh issue will be reduced accordingly. Proceeds from the IPO to the tune of Rs 152.54 crore will be allocated towards expansion and equipment, including Rs 126.32 crore for setting up new Krispy Kreme cloud kitchens, restaurants, kiosks, and central kitchens; Rs 19.91 crore for expanding certain existing cloud kitchens through brand additions, and Rs 6.31 crore for purchasing machinery and equipment. In addition, Rs 126.93 crore will be used for payment of debt, Rs 40 crore for lease payments for the company's current properties in India and Rs 14 crore on sales and marketing efforts. Also, the company plans to invest Rs 91.96 crore in its subsidiary, Fan Hospitality Services, another Rs 11.35 crore will be invested in Cakezone Foodtechs and Rs 81.15 crore will be used for acquiring further shareholding in three subsidiaries -- Millet Express Foods, Munchbox Frozen Foods and Yum Plum. A portion of the proceeds will also be earmarked for funding future acquisitions and strategic initiatives, along with general corporate purposes. Curefoods India is an internet-driven multi-brand food services company offering comprehensive cuisines. Its multi-channel approach includes providing food offerings to customers under its brands through delivery and non-delivery channels, comprising cloud kitchens, kiosks, and restaurants. JM Financial, IIFL Capital Services and Nuvama Wealth Management are the book-running lead managers to the public issue.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store